This article is more than 5 years old. Information may no longer be current.
CARDia
Coronary Artery Revascularization in Diabetes
Click Here to Manage Email Alerts
Trial was conducted to compare safety and efficacy of PCI with stenting vs. CABG in patients with diabetes and symptomatic multivessel CAD.
Design: randomized
Patients: 510
Centers: multicenter
Country: United Kingdom
RESULTS: The rate for the combination of death, MI and stroke in the CABG group was 10.5% vs. 13% for the PCI group. The noninferiority margin of 1.3 was exceeded by the upper limit of the CI for the primary study endpoint, signaling that the results did not suggest PCI was noninferior to CABG. All-cause mortality in the CABG group was 3.2% vs. 3.2% in the PCI group (P=.97), with revascularization rates of 2% in the CABG group vs. 11.8% in the PCI group (P<.001). The composite of major adverse coronary and cerebral events combining repeat revascularization with the primary endpoint was 11.3% in the CABG group vs. 19.3% in the PCI group (P=.016). The occurrence rate of TIMI major bleeding was higher in the CABG group vs. the PCI group (6.1% vs. 1.2%; P=.009).
Published in: J Am Coll Cardiol. 2010;55:432-440.
Click here to read more about the CARDia trial.